Skip to content

Confo Therapeutics

Active
Public limited companyfounded 201511 yrs activeTechnologiepark-Zwijnaarde 30, 9052 Gent, BelgiumKBO/BCE: BE 0632.474.939
Summary

Confo Therapeutics has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €33.29M and a net result of €-17.41M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 82% of 190 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Checked score

Score 2025
69 / 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency100=
Growth35▼-33
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €17k at 30 days acceptable
Liquidity ample (current ratio 10.79 against 21.17 in 2024; short-term debt: 8.9% and cash: 16.3% of total assets), and 11.9% of the assets are financed with debt.
Credit advice for your own amount and term

Signals

Five signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
88.1%
Return on assets
-46.1%
Age of the figures
9 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
18202122232425
2018 to 2025 · latest year €-17.41M
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
53 d early
2024
49 d early
2023
14 d early
2022
56 d early
2021
27 d early
2020
38 d early
2019
46 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover
€177k▼ 86.1%
2024 · €1.27M
2022: €500k 2023: €46.55M 2024: €1.27M
2022 → 2025
EBIT margin
-11041.5%▼ 10046.0pp
2024 · -995.5%
2022: -3147.5% 2023: 67.3% 2024: -995.5%
2022 → 2025
Net result
€-17.41M▼ 53.6%
2024 · €-11.34M
2018: €-3.50M 2020: €-8.87M 2021: €-9.85M 2022: €-15.59M 2023: €31.13M 2024: €-11.34M
2018 → 2025
Working capital
€33.07M▼ 34.8%
2024 · €50.72M
2018: €7.03M 2020: €10.71M 2021: €12.92M 2022: €-5.94M 2023: €25.61M 2024: €50.72M
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Turnover€500k€46.55M▲ 9,210%€1.27M▼ 97.3%€177k▼ 86.1%
Equity€8.02M-€-7.56M€23.57M€50.63M▲ 115%€33.29M▼ 34.3%
Operating result€-10.36M-€-15.74M▼ 51.8%€31.32M€-12.69M€-19.51M▼ 53.8%
Net result€-9.85M-€-15.59M▼ 58.2%€31.13M€-11.34M€-17.41M▼ 53.6%
Result per fiscal year
Operating resultNet result
€-20.00M€0€20.00M€40.00MOperating result 2021: €-10.36M€-10.36MNet result 2021: €-9.85M€-9.85MOperating result 2022: €-15.74M€-15.74MNet result 2022: €-15.59M€-15.59MOperating result 2023: €31.32M€31.32MNet result 2023: €31.13M€31.13MOperating result 2024: €-12.69M€-12.69MNet result 2024: €-11.34M€-11.34MOperating result 2025: €-19.51M€-19.51MNet result 2025: €-17.41M€-17.41M20212022202320242025€-20M€0€20M€40MOperating result 2023: €31.32M€31MNet result 2023: €31.13M€31MOperating result 2024: €-12.69M€-13MNet result 2024: €-11.34M€-11MOperating result 2025: €-19.51M€-20MNet result 2025: €-17.41M€-17M202320242025
The operating result stays negative: a loss of €19.51M in 2025 against €12.69M in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €37.77M
Fixed assets €1.32M ▼ 14.5%
Current assets €36.45M ▼ 31.5%
Equity and liabilities €37.77M
Equity €33.29M ▼ 34.3%
Debt €4.48M ▲ 8.0%
Debt's share of the balance-sheet total rises from 7.6% to 11.9%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€-949k
2024 · €-12.00M
Cash flow
€1.16M
2024 · €-10.65M
Current ratio
10.79
2024 · 21.17
Debt to equity
0.13
2024 · 0.08
ROE
-52.3%
2024 · -22.4%
ROA
-46.1%
2024 · -20.7%
Interest coverage
-84.82
2024 · -181.00
Debt ≤ 1 year
€3.38M
2024 · €2.51M
Debt > 1 year
€56k
2024 · €151k
Income taxes
€-1.32M
2024 · €-318k
Staff costs
€6.98M
2024 · €5.97M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 68 lines
Balance sheet Code20242025
Assets
Total assets20/58€54.78M€37.77M
Fixed assets21/28€1.55M€1.32M
Intangible fixed assets21€0-
Tangible fixed assets22/27€1.55M€1.32M
Plant, machinery and equipment23€1.27M€1.11M
Furniture and vehicles24€283k€210k
Current assets29/58€53.24M€36.45M
Amounts receivable after more than one year29€3.43M€4.01M
Other amounts receivable291€3.43M€4.01M
Amounts receivable within one year40/41€2.10M€2.13M
Trade receivables40€6k€0
Other amounts receivable41€2.09M€2.13M
Current investments50/53€41.90M€23.07M
Other investments51/53€41.90M€23.07M
Cash at bank and in hand54/58€5.07M€6.16M
Deferred charges and accrued income490/1€731k€1.08M
Equity and liabilities
Total equity and liabilities10/49€54.78M€37.77M
Equity10/15€50.63M€33.29M
Contributions10/11€76.77M€76.77M=
Capital10€50.79M€50.79M=
Issued capital100€50.79M€50.79M=
Outside capital11€25.98M€25.98M=
Share premium1100/10€25.98M€25.98M=
Reserves13€18.31M€18.37M
Non-distributable reserves130/1€345k€406k
Other1319€345k€406k
Tax-exempt reserves132€17.97M€17.97M=
Profit (loss) carried forward14€-44.45M€-61.85M
Amounts payable17/49€4.15M€4.48M
Amounts payable after more than one year17€151k€56k
Financial debts170/4€151k€56k
Credit institutions173€151k€56k
Amounts payable within one year42/48€2.51M€3.38M
Current portion of amounts payable after more than one year42€93k€95k
Trade debts44€1.47M€1.81M
Suppliers440/4€1.47M€1.81M
Taxes, remuneration and social security45€951k€1.48M
Remuneration and social security454/9€951k€1.48M
Accrued charges and deferred income492/3€1.49M€1.05M
Income statement Code20242025
Operating income70/76A€4.28M€20.10M
Turnover70€1.27M€177k
Own construction capitalised72-€17.96M
Other operating income74€3.00M€1.97M
Operating charges60/66A€16.96M€39.62M
Goods for resale, raw materials and consumables60€733k€1.21M
Purchases600/8€733k€1.21M
Services and other goods61€9.57M€12.86M
Remuneration, social security and pensions62€5.97M€6.98M
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€690k€18.56M
Operating profit (loss)9901€-12.69M€-19.51M
Financial income75/76B€1.21M€835k
Recurring financial income75€1.21M€835k
Income from current assets751€1.18M€683k
Other financial income752/9€30k€152k
Financial charges65/66B€176k€48k
Recurring financial charges65€176k€48k
Debt charges650€66k€11k
Other financial charges652/9€109k€37k
Profit (loss) for the period before taxes9903€-11.65M€-18.73M
Income taxes67/77€-318k€-1.32M
Taxes670/3€354k€221k
Tax adjustments and reversals of tax provisions77€672k€1.54M
Profit (loss) for the period9904€-11.34M€-17.41M
Transfer from tax-exempt reserves789€134k-
Profit (loss) for the period to be appropriated9905€-11.20M€-17.41M
Appropriation of the result
Profit (loss) to be appropriated9906€-44.45M€-61.85M
Profit (loss) brought forward from the previous period14P€-33.25M€-44.45M
Social balance
Average headcount (FTE)908752.059.0

The notes to these accounts (48 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
08-06
NBB filing Annual accounts filed
fiscal year 2025 · full schema
04-03
State Gazette act Appointments: CVBioConsulting BV, Stephen Dowd and 10 others
Permanent representatives: Cedric Ververken, Frank Landolt and Varun Gupta18 facts ▸
  • Board meeting, 13/02/2026
  • Director appointment, CVBioConsulting BV (chief executive officer (ceo), belast met het dagelijks bestuur)
  • Permanent representative, Cedric Ververken
  • Director appointment, Stephen Dowd (chief business officer (cbo))
  • Director appointment, Aquilexis BV (chief counsel intellectual property)
  • Permanent representative, Frank Landolt
  • Director appointment, Paolo Vicini (chief development officer (cdo))
  • Director appointment, CVBioConsulting BV (chief executive officer (ceo))
  • Permanent representative, Cedric Ververken
  • Director appointment, Christel Menet (chief scientific officer (cso))
  • Director appointment, Wellington Partners Life Sciences V GmbH & Co. KG (investeerder bestuurder)
  • Permanent representative, Varun Gupta
  • +6 further facts in this act
26-01
State Gazette act Statutes amendment
Share issue · Bank account3 facts ▸
  • Share issue, 2750, uitoefening van inschrijvingsrechten
  • Bank account, 16-12-2025
  • Statutes amendment, 15.1
2025
31-12
Financial Weakest financial yearnet €-17.41M
Net result drops to €-17.41M, the lowest in the series.
26-11
State Gazette act Statutes amendment
Share cancellation · Share issue · Power of attorney7 facts ▸
  • General meeting, 13/11/2025
  • Share cancellation, vervallen ESOP Inschrijvingsrechten, 225092
  • Share cancellation, Niet-toegekende ESOP Inschrijvingsrechten, 210153
  • Share issue, ESOP 2025 Inschrijvingsrechten, 435245
  • Statutes amendment
  • Power of attorney, VANHULLE Florence
  • Power of attorney, NautaDutilth
28-07
State Gazette act Reappointments: Dieter Weinand (independent director) and Robert Scott (independent director)
Permanent representatives: Varun Gupta, Cedric Ververken and Pieter-Jan Van Durme · Appointments: Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises (statutory auditor) and CVBioConsulting BV (chief executive officer / dagelijks bestuur) · Share issue10 facts ▸
  • General meeting, 09/07/2025
  • Share issue, inschrijvingsrechten op winstbewijzen
  • Statutes amendment, 15.1
  • Director reappointment, Dieter Weinand (independent director)
  • Director reappointment, Robert Scott (independent director)
  • Permanent representative, Varun Gupta
  • Permanent representative, Cedric Ververken
  • Permanent representative, Pieter-Jan Van Durme
  • Auditor appointment, Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises (statutory auditor)
  • Director appointment, CVBioConsulting BV (chief executive officer (ceo) / dagelijks bestuur)
12-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
16-01
State Gazette act Statutes amendment
Share cancellation · Share issue · Preemption waiver7 facts ▸
  • General meeting, 24-12-2024
  • Share cancellation, Vernietiging van 21.283 Niet-toegekende ESOP Inschrijvingsrechten (639 uit 2015 I, 4.236 uit 2015 II, 16.408 uit 2019)
  • Share issue, Uitgifte van 1.012.056 ESOP 2024 Inschrijvingsrechten
  • Statutes amendment
  • Preemption waiver, Verzaking aan de uitoefening van het voorkeurrecht
  • Board mandate, Volmacht aan de raad van bestuur voor de vaststelling van de identiteit van de begunstigden en het aantal aangeboden ESOP 2024 Inschrijvingsrechten en de uitoef…
  • Cash contribution, Bijkomende inbreng in geld onder opschortende voorwaarde en uitgifte van maximaal 1.012.056 nieuwe winstbewijzen die het kapitaal niet vertegenwoordigen
2024
31-12
Financial Liquidity times 8current ratio 21.17
Current ratio from 2.50 to 21.17; short-term debt falls from €17.04M to €2.51M.
31-12
Financial Equity above €50MEq €50.63M ▲115%
Equity rises from €23.57M to €50.63M.
31-07
State Gazette act Miscellaneous
Share issue · Statutes amendment · Power of attorney3 facts ▸
  • Share issue, winstbewijzen uitgegeven naar aanleiding van de uitoefening van inschrijvingsrechten
  • Statutes amendment, 13 bis, eerste punt
  • Power of attorney, iedere bestuurder van de Vennootschap, elk individueel handelend
31-07
State Gazette act Capital & shares · Statutes amendment · Resignations & appointments
Capital increase3 facts ▸
  • General meeting, 18 juli 2024
  • Capital increase, €11.423.615,45
  • Capital increase, €10.862.694,15
96.1% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
Show earlier events
17-07
NBB filing Annual accounts filed
fiscal year 2023 · full schema
11-06
State Gazette act Permanent representatives: Karl Nägler, Varun Gupta and 2 others
5 facts ▸
  • Board meeting, 23-05-2024
  • Permanent representative, Karl Nägler
  • Permanent representative, Varun Gupta
  • Permanent representative, Bart De Taeye
  • Permanent representative, Cedric Ververken
29-03
State Gazette act Miscellaneous
Share issue · Bank account · Statutes amendment4 facts ▸
  • Share issue, Winstbewijzen, 500
  • Bank account, 28/02/2024
  • Statutes amendment, 13 bis, eerste punt
  • Power of attorney, iedere bestuurder van de Vennootschap
01-03
State Gazette act Statutes amendment
Capital3 facts ▸
  • General meeting, 19-02-2024
  • Capital, €28.502.992
  • Statutes amendment
07-02
State Gazette act Permanent representative: Bart De Taeye
Appointments: Bart De Taeye, Kris Gler and 4 others8 facts ▸
  • Board meeting, 23-12-2023
  • Permanent representative, Bart De Taeye (permanent representative)
  • Director appointment, Bart De Taeye (director)
  • Director appointment, Kris Gler (director)
  • Director appointment, Wim Vandewalle (director)
  • Director appointment, Filip Goossens (director)
  • Director appointment, Johan Weinand (director)
  • Director appointment, Cedric Verleyen (dagselijks bestuur)
2023
31-12
Financial Back to profitnet €31.13M
Net result €31.13M after 4 loss-making years.
31-12
Financial Liquidity quadruplescurrent ratio 2.50
Current ratio from 0.66 to 2.50; short-term debt falls from €17.58M to €17.04M.
31-12
Financial Equity above €10MEq €23.57M
Equity rises from €-7.56M to €23.57M.
19-10
State Gazette act Resignations: John Berriman, Capricorn Partners NV and 5 others
Appointments: Dieter Weinand, ParticipatieMaatschappij Vlaanderen NV and 3 others · Permanent representatives: Jos Peeters, Filip Goossens and Karl Nägler17 facts ▸
  • Board meeting, 23/08/2023
  • General meeting, 25/08/2023
  • Director resignation, John Berriman (director and chair of the board)
  • Director appointment, Dieter Weinand (independent director)
  • Director resignation, Capricorn Partners NV (director)
  • Director resignation, ParticipatieMaatschappij Vlaanderen NV (director)
  • Director resignation, Wellington Partners Life Sciences V GmbH & Co.KG (director)
  • Director resignation, Edward van Wezel (director)
  • Director resignation, Christina Takke (director)
  • Director resignation, Caroline Goddeeris (director)
  • Director appointment, ParticipatieMaatschappij Vlaanderen NV (director)
  • Director appointment, Wellington Partners Life Sciences V GmbH & Co.KG (director)
  • +5 further facts in this act
05-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
2022
08-12
State Gazette act Permanent representatives: Ekaterina Smirnyagina and Jos Peeters
3 facts ▸
  • Board meeting, 15/09/2022
  • Permanent representative, Ekaterina Smirnyagina
  • Permanent representative, Jos Peeters
22-08
State Gazette act Reappointments: John Berriman, Robert Scott and 7 others
Permanent representatives: Jos Peeters, Filip Goossens and 2 others · Appointment: BDO Bedrijfsrevisoren (statutory auditor)15 facts ▸
  • General meeting, 30/06/2022
  • Director reappointment, John Berriman (independent director)
  • Director reappointment, Robert Scott (independent director)
  • Director reappointment, Capricorn Partners NV (director)
  • Director reappointment, Participatiemaatschappij Vlaanderen NV (director)
  • Director reappointment, Christina Takke (director)
  • Director reappointment, Caroline Goddeeris (director)
  • Director reappointment, Edward van Wezel (director)
  • Director reappointment, Wellington Partners Life Sciences V GmbH & Co. KG (director)
  • Director reappointment, Cedric Ververken (director)
  • Permanent representative, Jos Peeters
  • Permanent representative, Filip Goossens
  • +3 further facts in this act
25-07
State Gazette act Resignation: Alexandra Tolia (director)
Appointment: Caroline Goddeeris (director) · Permanent representatives: Jos Peeters, Filip Goossens and Karl Nägler · Mandate compensation7 facts ▸
  • General meeting, 31/05/2022
  • Director resignation, Alexandra Tolia (director)
  • Director appointment, Caroline Goddeeris (director)
  • Mandate compensation, Caroline Goddeeris
  • Permanent representative, Jos Peeters
  • Permanent representative, Filip Goossens
  • Permanent representative, Karl Nägler
22-07
State Gazette act Statutes amendment · Miscellaneous
Share issue · Bank account · Statutes amendment3 facts ▸
  • Share issue, Winstbewijzen, 639
  • Bank account, 29-06-2022
  • Statutes amendment
04-07
NBB filing Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
05-08
State Gazette act Reappointment: Cedric Ververken (director)
Permanent representative: Karl Nägler · Registered-office move5 facts ▸
  • General meeting, 03/06/2021
  • Director reappointment, Cedric Ververken (director)
  • Board meeting, 18/06/2021
  • Permanent representative, Karl Nägler
  • Registered-office move, Technologiepark-30, 9052 Zwijnaarde
13-07
State Gazette act Miscellaneous
Share issue · Bank account · Statutes amendment3 facts ▸
  • Share issue, Winstbewijzen, 2000
  • Bank account, 30 juni 2021
  • Statutes amendment
23-06
NBB filing Annual accounts filed
fiscal year 2020 · abbreviated schema
22-04
State Gazette act Permanent representative: Filip Goossens
2 facts ▸
  • Board meeting, 23/03/2021
  • Permanent representative, Filip Goossens
2020
31-12
Financial Equity above €10MEq €10.41M ▲34.7%
Equity rises from €7.73M to €10.41M.
29-06
State Gazette act Appointment: Rob Scott (independent director)
Permanent representative: Roderick Verhelst · Power of attorney4 facts ▸
  • General meeting, 04/06/2020
  • Director appointment, Rob Scott (independent director)
  • Permanent representative, Roderick Verhelst
  • Power of attorney, NautaDutilh
15-06
NBB filing Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
02-07
State Gazette act Reappointment: John Berriman (director)
Permanent representatives: Katya Smirnyagina, Chris De Jonghe and 2 others · Appointments: BDO Bedrijfsrevisoren, Christina Takke and 6 others · Power of attorney16 facts ▸
  • General meeting, 06/06/2019
  • Director reappointment, John Berriman (director)
  • Permanent representative, Katya Smirnyagina
  • Permanent representative, Chris De Jonghe
  • Permanent representative, Dr. Marianne Mertens
  • Permanent representative, Veerle Catry
  • Auditor appointment, BDO Bedrijfsrevisoren (statutory auditor)
  • Power of attorney, NautaDutilh
  • Number of directors, 8
  • Director appointment, Christina Takke (director)
  • Director appointment, Capricorn Venture Partners NE (director)
  • Director appointment, Participatiemaatschappij Vlaanderen NV (director)
  • +4 further facts in this act
13-06
NBB filing Annual accounts filed
fiscal year 2018 · abbreviated schema
24-05
State Gazette act Resignation: Johan Cardoen (director)
Capital increase · Bank account · Share issue17 facts ▸
  • General meeting, 29/04/2019
  • Capital increase, €13.002.988
  • Bank account, BE46 7350 5421 8136
  • Share issue, 650.149, opschortende voorwaarde conversie Klasse B2 Aandelen
  • Capital increase
  • Share issue, 16.667, uitgifte
  • Capital increase
  • Share issue, 15, Anti-Dilutie Warrants B2
  • Capital increase
  • Share issue, 3, IPO Warrants
  • Capital increase
  • Share issue, 582.485, warrants op winstbewijzen
  • +5 further facts in this act
13-03
State Gazette act Appointment: Edward van Wezel (investeerder bestuurder)
Permanent representatives: Katya Smirnyagina and Chris De Jonghe · Registered-office move · Power of attorney9 facts ▸
  • Board meeting, 07/02/2019
  • Registered-office move, Technologiepark-Zwijnaarde 94, 9052 Gent
  • Power of attorney, NautaDutilh
  • General meeting, 18/02/2019
  • Director appointment, Edward van Wezel (investeerder bestuurder)
  • Mandate compensation, Edward van Wezel
  • Power of attorney, NautaDutilh
  • Permanent representative, Katya Smirnyagina
  • Permanent representative, Chris De Jonghe
2018
31-12
State Gazette act Capital & shares
Capital increase · Bank account · Share issue22 facts ▸
  • General meeting, 14/12/2018
  • Capital increase, €6.666.672
  • Bank account, BE02 7370 4978 9840
  • Capital increase, €133.332
  • Share issue, winstbewijzen klasse B3, 33.333
  • Share issue, Anti-Dilutie Warrants B2, 45
  • Share issue, Anti-Dilutie Warrants B3, 5
  • Share issue, IPO Warrants, 10
  • Share issue, warrants op winstbewijzen, 300.000
  • Share issue, winstbewijzen, 300.000
  • Share issue, winstbewijzen klasse B2, 333.332
  • Share cancellation, IPO Warrants, 10
  • +10 further facts in this act
87.8% of this act was read; anything after the cut is not in this list.Read the act at the Belgisch Staatsblad ↗
10-08
State Gazette act Resignation: Els Beirnaert (director)
Appointment: Johan Cardoen (director) · Permanent representatives: Katya Smirnyagina and Chris De Jonghe · Mandate compensation6 facts ▸
  • General meeting, 17/07/2018
  • Director resignation, Els Beirnaert (director)
  • Director appointment, Johan Cardoen (director)
  • Mandate compensation, Johan Cardoen
  • Permanent representative, Katya Smirnyagina
  • Permanent representative, Chris De Jonghe
19-06
NBB filing Annual accounts filed
fiscal year 2017 · abbreviated schema
05-04
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting, 02/02/2018
  • Registered-office move, Confo Therapeutics Technologiepark 4 -9052 Zwijnaarde
01-02
State Gazette act Resignation: Vlaams Innovatiefonds Comm.VA (director)
Appointment: ParticipatieMaatschappij Vlaanderen NV (investeerder bestuurder) · Permanent representative: Chris De Jonghe · Mandate compensation6 facts ▸
  • General meeting, 22/12/2017
  • Director resignation, Vlaams Innovatiefonds Comm.VA (director)
  • Director appointment, ParticipatieMaatschappij Vlaanderen NV (investeerder bestuurder)
  • Mandate compensation, ParticipatieMaatschappij Vlaanderen NV
  • Permanent representative, Chris De Jonghe
  • Power of attorney, NautaDutilh
2017
08-06
NBB filing Annual accounts filed
fiscal year 2016 · abbreviated schema
02-01
State Gazette act Appointments: Cedric Ververken (director) and John Edward Berriman (bestuurder)
Resignation: Stephane van Rooijen (director) · Power of attorney5 facts ▸
  • General meeting, 12-12-2016
  • Director appointment, Cedric Ververken (director)
  • Director resignation, Stephane van Rooijen
  • Director appointment, John Edward Berriman ((onafhankelijk) bestuurder)
  • Power of attorney, NautaDutilh
2016
14-10
State Gazette act Resignations: Stephane van Rooijen (director) and Toulon BVBA (day-to-day manager)
Appointments: Cedric Ververken (director) and CVBIOCONSULTING BVBA (day-to-day manager) · Mandate compensation7 facts ▸
  • Board meeting, 08/09/2016
  • Director resignation, Stephane van Rooijen (director)
  • Director appointment, Cedric Ververken (director)
  • Mandate compensation, Cedric Ververken
  • Director resignation, Toulon BVBA (day-to-day manager)
  • Board meeting, 30/09/2016
  • Director appointment, CVBIOCONSULTING BVBA (day-to-day manager)
13-10
State Gazette act Statutes amendment
1 fact ▸
  • Statutes amendment
18-01
State Gazette act Appointments: Vlaams Innovatiefonds Comm.VA, TAKKE Christina and ZABEAU Marc
Permanent representative: DE JONGHE Chris · Capital increase · Bank account17 facts ▸
  • General meeting, 23/12/2015
  • Capital increase, €3.200.000
  • Bank account, BE92 7390 1299 0523
  • Capital, €8.700.000
  • Share issue, 3, IPO Warrants
  • Share issue, 15, Anti-Dilutie Warrants
  • Share issue, 141050, Warrants op Winstbewijzen
  • Statutes amendment
  • Director appointment, Vlaams Innovatiefonds Comm.VA (investeerder bestuurder)
  • Director appointment, TAKKE Christina (investeerder bestuurder)
  • Director appointment, ZABEAU Marc (investeerder bestuurder)
  • Mandate compensation, Confo Therapeutics
  • +5 further facts in this act
2015
20-10
State Gazette act Appointment: BDO Bedrijfsrevisoren (statutory auditor)
Permanent representative: Veerle Catry · Capital increase · Bank account15 facts ▸
  • General meeting, 29/09/2015
  • Capital increase, €500.000
  • Bank account, BE15 7360 1969 7330 bij KBC Bank NV
  • Capital, €5.500.000
  • Share issue, voorwaarden opgenomen in het document genaamd 'Plan houdende de uitgifte en de voorwaarden van een (1) IPO Warrant', 1 IPO Warrant
  • Share issue, voorwaarden opgenomen in het document genaamd 'Plan houdende de uitgifte en de voorwaarden van vijf (5) Anti-Dilutie Warrants', 5 Anti-Dilutie Warrants
  • Warrant modification, Wijziging van de voorwaarden van de 25 Anti-Dilutie Warrants uitgegeven op 19 juni 2015
  • Share issue, voorwaarden opgenomen in het document genaamd 'Plan houdende de uitgifte en de voorwaarden van 242.650 Warrants op Winstbewijzen', 242.650 warrants op winstbewi…
  • Power of attorney, 2 bestuurders gezamenlijk handelend
  • Power of attorney, 2 bestuurders gezamenlijk handelend
  • Power of attorney, raad van bestuur
  • Power of attorney, raad van bestuur
  • +3 further facts in this act
13-08
State Gazette act Appointment: Toulon BVBA (algemeen directeur/ceo)
Permanent representative: Stéphane Van Rooijen3 facts ▸
  • Board meeting, 18/06/2015
  • Director appointment, Toulon BVBA (algemeen directeur/ceo)
  • Permanent representative, Stéphane Van Rooijen
14-07
State Gazette act Capital & shares
Share issue · Power of attorney · Capital increase7 facts ▸
  • General meeting, 19/06/2015
  • Share issue, Uitgifte van 6 IPO Warrants
  • Share issue, Uitgifte van 25 Anti-Dilutie Warrants
  • Power of attorney, 2 bestuurders gezamenlijk handelend
  • Power of attorney, 2 bestuurders gezamenlijk handelend
  • Capital increase
  • Capital increase
25-06
State Gazette act Incorporation
Appointments: Stéphane VAN ROOIJEN, Els BEIRNAERT and 2 others · Permanent representative: Katya SMIRNYAGINA · Founder25 facts ▸
  • Incorporation, 11/06/2015
  • Founder, VIB (Vlaams Instituut voor Biotechnologie)
  • Founder, Capricorn Health-Tech Fund
  • Founder, Vlaams Gewest
  • Founder, QBIC Arkiv Fund
  • Founder, QBIC Brussels Fund
  • Founder, QBIC Feeder Fund
  • Founding capital, €5.000.000
  • Bank account, BE89 7360 1318 4485 bij de KBC Bank
  • Director appointment, Stéphane VAN ROOIJEN (director)
  • Director appointment, Els BEIRNAERT (director)
  • Director appointment, Capricorn Venture Partners (director)
  • +13 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
30 directors, last change in 2026
VANGINDERTAEL Jeroen
Investeerder bestuurder · since 11-02-2026
Current
AQUILEXIS
Chief counsel intellectual property · since 01-01-2026 · Private limited company · perm. rep.: Frank Landolt
Current
Christel Menet
Chief scientific officer (cso) · since 01-01-2026
Current
Paolo Vicini
Chief development officer (cdo) · since 01-01-2026
Current
Stephen Dowd
Chief business officer (cbo) · since 01-01-2026
Current
CVBioConsulting BV
Chief executive officer (ceo) / dagelijks bestuur · since 28-07-2025 · Legal entity · perm. rep.: Cedric Ververken
Current
24 other directors
CVBIOCONSULTING
Chief executive officer (ceo) · since 18-07-2024 · Private limited company · perm. rep.: Cedric Ververken
Current
Bart De Taeye
Director · since 25-01-2024
Current
Cedric Verleyen
Dagselijks bestuur · since 25-01-2024
Current
Filip Goossens
Director · since 25-01-2024
Current
Johan Weinand
Director · since 25-01-2024
Current
Kris Gler
Director · since 25-01-2024
Current
Wim Vandewalle
Director · since 25-01-2024
Current
Dieter Weinand
Independent director · since 25-08-2023
Current
GODDEERIS Caroline
Investeerder bestuurder · since 25-08-2023
Current
Participatiemaatschappij Vlaanderen
Director · since 25-08-2023 · Public limited company · perm. rep.: Filip Goossens
Current
VAN WEZEL Edward
Investeerder bestuurder · since 25-08-2023
Current
Wellington Partners Life Sciences V GmbH & Co. KG
Investeerder bestuurder · since 25-08-2023 · Legal entity · perm. rep.: Karl Nägler
Current
Capricorn Partners NV
Director · since 30-06-2022 · Legal entity · perm. rep.: Jos Peeters
Current
Robert Scott
Independent director · since 30-06-2022
Current
Participatiemaatschappij Vlaanderen NV
Director · since 02-07-2019 · Legal entity · perm. rep.: Chris De Jonghe
Current
Cedric Ververken
Director · since 08-09-2016
Current
Rob Scott
Independent director · since 04-06-2020
Not recently confirmed
Capricorn Venture Partners NE
Director · since 02-07-2019 · Legal entity · perm. rep.: Katya Smirnyagina
Not recently confirmed
John Edward Berriman
(onafhankelijk) bestuurder · since 12-12-2016
Not recently confirmed
CVBIOCONSULTING BVBA
Day-to-day manager · since 01-10-2016 · Legal entity
Not recently confirmed
Marc ZABEAU
Investeerder bestuurder · since 11-06-2015
Not recently confirmed
VLAAMS INNOVATIEFONDS
Investeerder bestuurder · since 23-12-2015 · Legal entity · perm. rep.: DE JONGHE Chris
Not recently confirmed
TOULON
Algemeen directeur/ceo · since 18-06-2015 · Private limited company · perm. rep.: Stéphane Van Rooijen
Not recently confirmed
Capricorn Venture Partners
Director · since 11-06-2015 · Legal entity · perm. rep.: Katya SMIRNYAGINA
Not recently confirmed
11-02-2026 VANGINDERTAEL Jeroen: Appointed as Investeerder bestuurder
11-02-2026 Dieter Weinand: Appointed as Independent director
11-02-2026 GODDEERIS Caroline: Appointed as Investeerder bestuurder
11-02-2026 VAN WEZEL Edward: Appointed as Investeerder bestuurder
11-02-2026 Wellington Partners Life Sciences V GmbH & Co. KG: Appointed as Investeerder bestuurder
Full history in the Timeline (71 changes) →
Not every act has been read: a resignation may be missing here
2 acts were read only in part. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2015
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Technologiepark-Zwijnaarde 309052 Gent
Ground area
9,447 m²
Building footprint
2,132 m²
Volume, LiDAR
34,234 m³
Parcel 44082B0087/00E000, Flanders · tallest building 21.5 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
Confo Therapeutics
Technologiepark-Zwijnaarde 30, 9052 GentScientific research and development
since 20152.244.335.124
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44082B0087/00E000 Flanders 9,447 m² 1 · 2,132 m² 21.5 m · 5 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor
Deloitte Bedrijfsrevisoren/Réviseurs d’EntreprisesCurrent
Statutory auditor · represented by Pieter-Jan Van Durme
28-07-2025 → present
Show 2 earlier auditors
BDO Bedrijfsrevisoren
Statutory auditor · represented by Veerle Catry
succeeded by BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES in 2022
20-10-2015 → 22-08-2022
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
Statutory auditor · represented by Veerle Catry
succeeded by Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises in 2025
22-08-2022 → 28-07-2025

Articles of association

Purpose
De Vennootschap heeft tot voorwerp, in België en in het buitenland, zowel voor eigen rekening als voor rekening van derden, alleen of in participatie met derden: a) Het exploiteren…
Full purpose

De Vennootschap heeft tot voorwerp, in België en in het buitenland, zowel voor eigen rekening als voor rekening van derden, alleen of in participatie met derden: a) Het exploiteren van biologische, chemische of andere producten, processen en technologieën in de life sciences sector in het algemeen en in de farmaceutische, medische en chemische sector, inclusief veterinaire producten in het bijzonder. Onder exploiteren wordt mede verstaan activiteiten met betrekking tot onderzoek, ontwikkeling, productie, marketing en exploitatie. b) Het wereldwijd verspreiden van, verkopen van en service verlenen met betrekking tot de producten van de Vennootschap direct aan klanten en tevens via derden. c) Het oprichten van, het deelnemen in, beheren van, toezicht houden op en samenwerken met vennootschappen en andere ondernemingen, het verkrijgen, behouden, vervreemden of op andere wijze beheren van deelnemingen en belangen in andere vennootschappen en ondernemingen. d) Het financieren van vennootschappen en andere ondernemingen, het lenen, uitlenen en bijeenbrengen van gelden, het deelnemen in financiële transacties, daaronder begrepen, het uitgeven van obligaties, schuldbrieven, of andere waardepapieren, alsmede het aangaan van alle daarmee enigszins samenhangende overeenkomsten. e) Het verstrekken van adviezen, en het verlenen van diensten aan ondernemingen en vennootschappen waarmee de Vennootschap in een groep is verbonden en aan derden. f) Het verstrekken van garanties, het verbinden van de Vennootschap en het bezwaren van activa van de Vennootschap ten behoeve van ondernemingen en vennootschappen waarmee de Vennootschap in een groep is verbonden en ten behoeve van derden. g) Het verkrijgen, beheren, exploiteren en vervreemden van roerende goederen, onroerende goederen en van alle vermogenswaarden in het algemeen. h) Het verhandelen van valuta, effecten, roerende goederen, onroerende goederen en vermogenswaarden in het algemeen. i) Het verkrijgen van, exploiteren en verhandelen van octrooien, merkrechten, vergunningen, knowhow en andere industriële eigendomsrechten. j) Het verrichten van alle soorten industriële, financiële en commerciële activiteiten.

Structure & network

Connections & network

43 connected companies
Cedric Ververken, Shared director CVCedric VerverkenCVBIOCONSULTING, via Cedric Ververken CCVBIOCONSULTING+33 companies via a shared corporate director +33via a sharedcorporate director+3 companies via a shared director +3via a shareddirectorBiotalys, Shared director BBiotalysComplix, Shared director CComplixEPICS THERAPEUTICS, Shared director ETEPICSTHERAPEUTICSTOULON, Shared director TTOULONVLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, Shared director VIVLAAMSINSTITUUT…LayerWise, Shared corporate director LLayerWiseConfo Therapeutics ConfoTherapeutics0632.474.939
Shared directorsBundled connections
Linked via shared directors
CVBIOCONSULTING
via Cedric Ververken · Permanent representative
Aphea.Bio
Shared director
Biotalys
Shared director
Complix
Shared director
Show 39 more companies with a shared director
EPICS THERAPEUTICS
Shared director
MyCartis
Shared director
ReWind Therapeutics
Shared director
TOULON
Shared director
Aelin Therapeutics
Shared corporate director
Banqup Group
Shared corporate director
Belgian Offshore Platform
Shared corporate director
BELWIND
Shared corporate director
BLUE GATE ANTWERP PUBLIC HOLDING
Shared corporate director
CITYMESH INTEGRATOR
Shared corporate director
DBFM Scholen van Morgen
Shared corporate director
De Werkvennootschap
Shared corporate director
DEME BLUE ENERGY
Shared corporate director
FEops
Shared corporate director
GIGARANT
Shared corporate director
HERSELF
Shared corporate director
Hubspot Belgium
Shared corporate director
iFLUX
Shared corporate director
Indigo Diabetes
Shared corporate director
INNOVATION FUND
Shared corporate director
InOpSys
Shared corporate director
InvestSuite
Shared corporate director
LayerWise
Shared corporate director
PARKWIND
Shared corporate director
Plopsa Station Antwerp
Shared corporate director
PMV - Standaardleningen
Shared corporate director
PROMAN Agilitas
Shared corporate director
REIN4CED
Shared corporate director
RENEWABLE ENERGY BASE OSTEND
Shared corporate director
RheaVita
Shared corporate director
ST Engineering iDirect (Europe) CY
Shared corporate director
STORM HOLDING 2
Shared corporate director
SupplyStack
Shared corporate director
THE BELGIAN CHOCOLATE EXPERIENCE
Shared corporate director
TRENDMINER
Shared corporate director
Vlaams Energiebedrijf
Shared corporate director
WANDELAAR INVEST
Shared corporate director

Capital and shareholders

Shareholders according to the acts
At incorporation act of 25-06-2015 ↗
  • VIB (Vlaams Instituut voor Biotechnologie) 500 shares · in kind
  • Capricorn Health-Tech Fund 375 shares · in cash
  • Vlaams Gewest 125 shares · in cash
  • QBIC Arkiv Fund 125 shares · in cash
  • QBIC Brussels Fund in cash
  • QBIC Feeder Fund in cash

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 31-07-2024 Capital increase of 11,423,615.45 EUR · to 39,926,607.45 EUR · in kind
  2. 31-07-2024 Capital increase of 10,862,694.15 EUR · to 50,789,301.60 EUR · in cash
  3. 01-03-2024 Capital stated in the act · 28,502,992 EUR · 7,175,748 shares
  4. 24-05-2019 Capital increase of 13,002,988 EUR · to 28,502,992 EUR
  5. 31-12-2018 Capital increase of 6,666,672 EUR · to 15,366,672 EUR · in cash
  6. 31-12-2018 Capital increase of 133,332 EUR · to 15,500,004 EUR · in kind
  7. 18-01-2016 Capital increase of 3,200,000 EUR · to 8,700,000 EUR
  8. 20-10-2015 Capital increase of 500,000 EUR · to 5,500,000 EUR
Show 1 older capital entries
  1. 25-06-2015 Incorporation · 5,000,000 EUR

Public money · subsidies and aid

Flemish government

2022 to 2025 · 12 entries · 6,687,658 EUR awarded · 5,283,547 EUR paid
Year Entries awardedpaid
2025 5 1,058,383 EUR831,389 EUR
2024 3 2,103,239 EUR2,456,136 EUR
2023 2 1,200 EUR1,995,606 EUR
2022 2 3,524,836 EUR416 EUR
Schemes
Onderzoeksproject
5 entries · 6,660,120 EUR · 5,256,009 EUR paid · Fonds voor Innoveren en Ondernemen
Baekeland-mandaat
1 entry · 16,533 EUR · 16,533 EUR paid · Fonds voor Innoveren en Ondernemen
Vlaams opleidingsverlof (VOV)
2 entries · 6,986 EUR · 6,986 EUR paid · Departement Werk en Sociale Economie
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
4 entries · 4,019 EUR · 4,019 EUR paid · Fonds voor Innoveren en Ondernemen

Similar companies · same sector, comparable size

Of 1,177 companies in sector 72109 we hold annual accounts for 715. 114 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification
Legal formPublic limited company
Founded11-06-2015
Fiscal year end31-12
Abbreviation NL Confo
Activities, NACEBEL 2025
72101Research and development on biotechnology
72109Other research and development on natural sciences
Sources
Crossroads Bank for EnterprisesNational Bank · 10 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.